List of Publicly Traded Companies that Provide Diagnostic Products
The global diagnostic sector is undergoing a massive shift toward liquid biopsy precision and Point-of-Care Testing (POCT), a market currently projected to grow at an 18% CAGR. Explore the 2026 leaders managing $184 billion portfolios and driving the next generation of multi-cancer early detection.
Navigating the List of Publicly Traded Companies that Provide Diagnostic Products in 2026 requires understanding the transition from traditional lab services to molecular precision. While established giants continue to scale their physician office networks, the sector is increasingly defined by the List of Publicly Traded Healthcare Companies that lead in genomic sequencing and liquid biopsy. High-growth firms like Natera are currently delivering nearly 90% revenue increases, signaling a fundamental shift in how oncologists approach cancer screening. Meanwhile, diversified leaders like Danaher (DHR #2 $138B) maintain massive footprints across life sciences and clinical diagnostics. This guide tracks the most influential public entities currently shaping the future of medical testing and clinical lab infrastructure.
Key Takeaways
The multi-cancer screening market, or liquid biopsy, has reached a $12B TAM, led by the rapid clinical adoption of Natera and Exact Sciences.
Point-of-Care Testing (POCT) is growing at an 18% CAGR as testing moves from central labs to retail pharmacies and home settings.
Traditional laboratory giants like Quest Diagnostics (DGX labs $16B) maintain defensive stability with massive physician networks and high-margin specialized testing.
AI-driven diagnostics are now a core differentiator, reducing error rates in pathology and accelerating FDA approval timelines for molecular pipelines. Compare these in the Diagnostics Industry Comparison Widget.
Top List of Publicly Traded Companies that Provide Diagnostic Products by Market Cap (2026)
The following table tracks the largest diagnostic product providers and lab service leaders currently trading on U.S. exchanges as of April 2026.
| Rank | Ticker | Company | Focus | Market Cap | 1Y Return | Diag. % Rev | Key Tech |
|---|---|---|---|---|---|---|---|
| 1 | TMO | Thermo Fisher Scientific | Lab/IVD | $184.0B | +12% | ~45% | Sequencing |
| 2 | DHR | Danaher Corporation | Clinical Diag | $138.0B | +15% | ~40% | Molecular |
| 3 | IDXX | IDEXX Laboratories | Veterinary Diag | $44.0B | +18% | 90% | In-Clinic |
| 4 | NTRA | Natera, Inc. | Precision Oncology | $27.0B | +89% | 95% | Liquid Biopsy |
| 5 | EXAS | Exact Sciences | Cancer Screening | $14.5B | +22% | 100% | Cologuard |
| 6 | DGX | Quest Diagnostics | Lab Services | $16.0B | +8% | 100% | Routine/Specialty |
| 7 | LH | Labcorp | Lab Services | $20.0B | +11% | 100% | Clinical Trials |
| 8 | GH | Guardant Health | Precision Diag | $4.2B | +35% | 100% | Blood-Based |
| 9 | BIO | Bio-Rad Laboratories | Life Sciences/Diag | $9.8B | +5% | 40% | PCR/Clinical |
| 10 | CSTL | Castle Biosciences | Dermatology Diag | $0.8B | +42% | 100% | Gene Expression |
List of Publicly Traded Companies that Provide Diagnostic Products — Complete Company List
List of Publicly Traded Companies that Provide Diagnostic Products Listed on Major U.S. Exchanges
- molecular diagnostics
- List of Publicly Traded Healthcare Companies
- Diagnostics Industry Comparison Widget
Diagnostics: Large -Cap Stocks
- Danaher Corporation (DHR) (Diversified Conglomerate: Environmental, dental, diagnostics, life sciences, industrial technologies, test & measurement)
- Grifols, S.A. (GRFS) (Spain, three primary divisions: 1)
- Hologic, Inc. (HOLX) (Diagnostic products, medical imaging systems and surgical products; women’s health)
- Quest Diagnostics Inc. (DGX) (Diagnostic testing services, diagnostic products, clinical trials testing, healthcare IT and wellness and risk management services)
Diagnostics: Mid -Cap Stocks
- Bio-Rad Laboratories, Inc. (BIO) (Life Science: laboratory instruments, apparatus, consumables and reagents; products for medical screening and diagnostics)
- Neogen Corporation (NEOG) (Products dedicated to food and animal safety)
- Opko Health Inc. (OPK) (Point-of-care diagnostics; molecular diagnostics, pharmaceuticals, vaccines)
- OraSure Technologies, Inc. (OSUR) (Point-of-care diagnostics and collection devices)
Diagnostics: Small-Cap Stocks
- Abaxis, Inc. (ABAX) (Point-of-care blood analyzers for humans and animals)
- Accelerate Diagnostics, Inc. (AXDX) (Tests for infectious pathogens)
- Heska Corporation (HSKA) (Veterinary diagnostic and specialty veterinary products)
- Meridian Bioscience Inc. (VIVO) (Tests for respiratory infections, parasitology, foodborne diseases)
- Oxford Immunotec Global Plc. (OXFD) (United Kingdom: immunology diagnostic company)
- Quanterix Corporation (QTRX) (IPO December 7, 2017; digital immunoassay platform)
- Quidel Corporation (QDEL) (Tests for infectious diseases, gastrointestinal diseases, women’s health)
- RadNet, Inc. (RDNT) (Fixed-site diagnostic imaging services through its over 250 outpatient imaging centers)
- SurModics, Inc. (SRDX) (Two core businesses: in vitro diagnostics and medical device coatings)
Diagnostics: Micro-Cap Stocks
- CareDx, Inc. (CDNA) (Diagnostics for use in the surveillance of organ transplant patients)
- Chembio Diagnostics, Inc. (CEMI) (Tests for infectious diseases)
- Digirad Corporation (DRAD) (Nuclear cardiology and ultrasound imaging, cardiac event monitoring services, medical diagnostic imaging systems)
- Lantheus Holdings, Inc. (LNTH) (IPO in June 2015: Diagnostic medical imaging agents; heart failure, coronary artery disease, peripheral vascular disease, strokes)
- Navidea Biopharmaceuticals, Inc. (NAVB) (Precision diagnostics, therapeutics and radiopharmaceutical agents)
- OncoCyte Corporation (OCX) (Liquid biopsy cancer diagnostic tests)
- Quotient Limited (QTNT) (United Kingdom: diagnostic transfusion services)
- Psychemedics Corporation (PMD) (Testing services through hair samples)
- T2 Biosystems, Inc. (TTOO) (Test for sepsis, hemostasis, lyme disease)
- Trinity Biotech Plc. (TRIB) (Ireland: tests for autoimmune disorders, cardiac arrest, diabetes, infectious diseases, sexually transmitted diseases)
- Vermillion, Inc. (VRML) (Diagnostics used to detect and improve the treatment of gynecologic disease in women)
- VolitionRX Limited (VNRX) (Singapore: diagnostic tests for cancer and other diseases)
Diagnostics: Nano-Cap Stocks
- Akers Biosciences Inc. (AKER) (Point-of-care screening and testing products)
- Biomerica, Inc. (BMRA) (Medical diagnostic products)
- Check-Cap Ltd. (CHEK) (IPO in January 2015, Israel: Ingestible imaging capsule for the screening for colorectal cancer)
- Interpace Diagnostics Group, Inc. (IDXG)
- ITUS Corporation (ITUS)
Risks & Considerations
Reimbursement Policy Shifts
Diagnostics companies are highly sensitive to CMS (Medicare/Medicaid) reimbursement rates; any sudden coding changes can immediately impact the profitability of molecular and liquid biopsy tests.
FDA Regulatory Hurdles
The transition of many Laboratory Developed Tests (LDTs) under stricter FDA oversight adds significant clinical trial costs and risk of market withdrawal for precision oncology firms.
Intense Pricing Compression
Routine testing in central labs faces ongoing pricing pressure from payors, requiring providers like Quest and Labcorp to constantly find operational efficiencies through AI and automation.
Competitive Technological Churn
The diagnostics field moves rapidly; a proprietary screening technology today can be rendered obsolete by a more sensitive or cost-effective sequencing platform tomorrow.